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*Salmonella enterica* is a bacterial pathogen that causes a variety of diseases in humans, including gastroenteritis, bacteremia, and typhoid fever ([@ref1]). In the 1990s, the prevalence of multidrug-resistant *Salmonella* increased in the United Kingdom ([@ref2], [@ref3]), the United States ([@ref4], [@ref5]), and Canada ([@ref6]). Many countries documented outbreaks associated with drug-resistant *Salmonella* in poultry, cattle, and swine ([@ref4], [@ref7]-[@ref10]). Emerging resistance to antibiotics in *Salmonella* has been found in both humans and animals and is a potentially serious public health problem ([@ref11], [@ref12]). High level fluoroquinolone resistance in *S. enterica* serovar Typhimurium phage type DT204 has been reported to result from multiple target gene mutations and active efflux by the AcrAB-TolC multidrug efflux pump ([@ref13], [@ref14]).

Multidrug efflux pumps have important physiological functions, including transport of drugs, bile salts, toxins, and environmental compounds ([@ref15], [@ref16]). In bacteria, drug resistance is often associated with multidrug efflux pumps that decrease cellular drug accumulation ([@ref17], [@ref18]). In bacteria, such pumps have been classified into five families on the basis of sequence similarity as follows: the major facilitator, resistance-nodulation-cell division, small multidrug resistance, multidrug and toxic compound extrusion, and ATP-binding cassette families ([@ref19]-[@ref21]). In Gram-negative bacteria, resistance-nodulation-cell division pumps are especially effective in generating resistance ([@ref17], [@ref22]-[@ref24]). Recent studies have shown that Gram-negative *S. enterica* serovar Typhimurium has nine functional drug efflux pumps ([@ref25]). Many multidrug pumps have overlapping substrate spectra, and it is intriguing that bacteria, with their economically organized genomes, harbor large sets of multidrug efflux genes ([@ref17]).

The key to understanding how bacteria utilize these pumps lies in the regulation of their expression ([@ref19], [@ref26]-[@ref28]). Currently available data indicate that multidrug efflux pumps are often expressed under precise and elaborate transcriptional control. For example, expression of *acrAB*, which encodes the AcrAB pump, may be subject to multiple levels of regulation. In *Escherichia coli*, it is modulated locally by the repressor AcrR ([@ref29]). At a more global level, it is modulated by stress conditions and by regulators such as MarA, SoxS, and Rob ([@ref30], [@ref31]). Olliver *et al.* ([@ref32]) reported that mutation in *acrR* contributes to overexpression of *acrAB* in *Salmonella* and increases resistance to multiple drugs. Eaves *et al.* ([@ref33]) reported that *acrB, acrF*, and *acrD* are coordinately regulated and that their expression influences expression of transcriptional activators *marA* and *soxS*. Furthermore, integration of IS1 and IS10 elements into the upstream region of the *acrEF* operon has been reported to cause increased expression of *acrEF* ([@ref34]). These examples illustrate the complexity and diversity of the mechanisms regulating bacterial multidrug efflux pumps. However, few data are available on signals that induce multidrug efflux genes in *Salmonella*.

Previously, it was reported that indole induces the *acrD, acrE, cusB, emrK, mdtA, mdtE*, and *mdtH* multidrug efflux pump genes in *E. coli* ([@ref35]). They also reported that indole induction of *acrD* and *mdtA* is mediated by the BaeSR and CpxAR systems. However, the effect of indole on the AcrAB-TolC multidrug efflux pump, which plays a major role in antibiotic resistance, remains unknown. Very few signals inducing multidrug efflux pumps in *Salmonella* have been identified so far. Here we report on induction of *acrAB* in *Salmonella* via the specific regulator RamA in response to indole, bile, and an *E. coli* conditioned medium. This study describes the dual regulatory mode of *acrAB* via RamA in response to environmental signals.

EXPERIMENTAL PROCEDURES
=======================

*Bacterial Strains, Plasmids, and Growth Conditions*---The bacterial strains and plasmids used in this study are listed in [Table 1](#tbl1){ref-type="table"}. The *S. enterica* serovar Typhimurium strains were derived from the wild-type (WT)[4](#fn3){ref-type="fn"} strain ATCC14028s ([@ref36]). P22-mediated transductions were performed as described by Davis *et al.*, ([@ref37]). Bacterial strains were grown at 37 °C in LuriaBertani (LB) broth or plates. Antibiotics such as ampicillin (100 μg/ml), kanamycin (25 μg/ml), or chloramphenicol (25 μg/ml) were added when required.

TABLE 1S. enterica strains and plasmids used in this study**Strain or plasmidOriginal nameCharacteristicsSource or Ref.Strains as in text**WTATCC14028s*S. enterica* serovar Typhimurium wild-type36*tolC-lac*EG15109Δ*tolC-lacZY*^+^ Km^R^25*acrAB-lac*NKS505Δ*acrAB-lacZY*^+^ Km^R^This study*acrEF-lac*EG15114Δ*acrEF-lacZY*^+^ Km^R^25*acrD-lac*EG15120Δ*acrD-lacZY*^+^ Km^R^25*mdtABC-lac*EG15124Δ*mdtABC-lacZY*^+^ Km^R^25*mdsABC-lac*NKS517Δ*mdsABC-lacZY*^+^ Km^R^This study*emrAB-lac*NKS522Δ*emrAB-lacZY*^+^ Km^R^This study*mdfA-lac*NKS524Δ*mdfA-lacZY*^+^ Km^R^This study*mdtK-lac*EG15132Δ*mdtK-lacZY*^+^ Km^R^25*macAB-lac*NKS530Δ*macAB-lacZY*^+^ Km^R^This studyΔ*baeSR cpxAR/acrAB-lac*NES56Δ*baeSR* Δ*cpxAR*::Cm^R^ Δ*acrAB-lacZY*^+^ Km^R^This studyΔ*baeSR cpxAR/acrD-lac*NES26Δ*baeSR* Δ*cpxAR*::Cm^R^ Δ*acrD-lacZY*^+^ Km^R^This studyΔ*marA/acrAB-lac*NES20Δ*marA*::Cm^R^ Δ*acrAB-lacZY*^+^ Km^R^This studyΔ*soxS/acrAB-lac*NES28Δ*soxS*::Cm^R^ Δ*acrAB-lacZY*^+^ Km^R^This studyΔ*rob/acrAB-lac*NES29Δ*rob*::Cm^R^ Δ*acrAB-lacZY*^+^ Km^R^This studyΔ*sdiA/acrAB-lac*NES35Δ*sdiA*::Cm^R^ Δ*acrAB-lacZY*^+^ Km^R^This studyΔ*acrR/acrAB-lac*NES48Δ*acrR*::Cm^R^ Δ*acrAB-lacZY*^+^ Km^R^This studyΔ*marA rob soxS sdiA acrR/acrAB-lac*NES55Δ*marA* Δ*rob* Δ*soxS* Δ*sdiA* Δ*acrR*::Cm^R^ Δ*acrAB-lacZY*^+^ Km^R^This studyΔ*ramA/acrAB-lac*NES58Δ*ramA*::Cm^R^ Δ*acrAB-lacZY*^+^ Km^R^This studyΔ*ramA/tolC-lac*NES65Δ*ramA*::Cm^R^ Δ*tolC-lacZY*^+^ Km^R^This study**Plasmids**pKD3rep~R6Kg\[r\]~Ap^R^FRT Cm^R^FRT39pKD4rep~R6Kg\[r\]ts~Ap^R^FRT Km^R^FRT39pCP20rep~pSC101~ Ap^R^ Cm^R^*cI857*lP~R~*flp*39pMALc2XVector, Amp^R^New England BiolabspMALc2X *ramA*-His~6~*ramA*-His~6~ gene cloned into pMALc2X, Amp^R^This studypMALc2X *ramA*-His~6~ (truncated)5 -Terminal (69 bp) deleted *ramA*-His~6~ gene cloned into pMALc2X, Amp^R^This studypNN387Single copy vector, Cm^R^, NotI-HindIII cloning site upstream of promoter-less *lacZ*38pNN*ramA*pNN387 (*ramA* gene promoter-*lacZ*)This study

*Plasmid Construction*---*ramA* was amplified by PCR from the genomic DNA of strain ATCC14028s ([@ref36]) using LA-Taq polymerase (Takara Bio Inc., Otsu, Japan) and the primers listed in [Table 2](#tbl2){ref-type="table"}. This process introduced the EcoRI and HindIII restriction sites. The PCR fragment was cloned between the EcoRI and HindIII sites of the pMAL-c2X vector (New England Biolabs Inc., Ipswich, MA). The *ramA* promoter was amplified by PCR, and the PCR fragment was cloned between the NotI and HindIII sites of the pNN387 vector ([@ref38]). The nucleotide sequences of the recombinant plasmids were determined using an ABI PRISM 3100-*Avant* genetic analyzer (Applied Biosystems Foster City, CA).

TABLE 2Primers used in this study**PrimerSequences (5′ to 3′)For gene deletion***marA*-P1TATTTGCTCAAGAAAATTCTGCCGTAGACAAAAAAGACGTGTGTAGGCTGGAGCTGCTTC*marA*-P2CAGCATTTTCATGGTGCTCTTCGCGTGGCGCATAAACAAACATATGAATATCCTCCTTAG*soxS*-P1GACAAAACGACGAATCGAATACTGTTTAAGAGGCAACAATGTGTAGGCTGGAGCTGCTTC*soxS*-P2GCCTCTGACGATACGCGGGCAGACGCCCTACAGGCGGTGACATATGAATATCCTCCTTAG*rob*-P1TGATATCGGGTGCTCGTTGTTGAAAGGATGGGGATATTTTGTGTAGGCTGGAGCTGCTTC*rob*-P2GCATCTGGACGCCCCTGCATTGGATGAGCTACAGCGTTAACATATGAATATCCTCCTTAG*sdiA*-P1ATAATAATGATTATCAATATCAAAGGCGTGACCATAAAATGTGTAGGCTGGAGCTGCTTC*sdiA*-P2TCAGCCGGTTTCGCGTCTGGCGCGAAGCATCGTCAGCACGCATATGAATATCCTCCTTAG*acrR*-P1AGCGACACAGAAAATGTCCAGGAGTTTTCCTGGAATATTAGTGTAGGCTGGAGCTGCTTC*acrR*-P2TAAATGTATGTAAATCTAACGCCTGTAAATTCACCGACATCATATGAATATCCTCCTTAG*ramA*-P1CCATGCGATAAGCTGTCTCACAATTTGTGTGGTTATTACTGTGTAGGCTGGAGCTGCTTC*ramA*-P2CGATTAAACATTTCAATGCGTACGGCCATGCTTTTCTTTACATATGAATATCCTCCTTAG**For plasmid construction***ramA*-F-EcoRI (for histidine-tagged RamA)GCGAATTCATGACCATTTCCGCTCAGG*ramA*-F-EcoRI (for N-terminal truncated RamA)GCGAATTCCGTATTGATGATATTGCC*ramA*-R-HindIIIGCAAGCTTTCAATGATGATGATGATGATGCGTACGGCCATGCTT*ramA*-F-NotI (for pNN387*ramA*)CGCGCGGCCGCGTTGTTTCAGCCAGCGCC*ramA*-R-HindIII (for pNN387*ramA*)GAGAAGCTTCGTGCTCTCCCCTCTATCAA**For EMSA***acrA*-PFCCATATGTCGGTGAATTTACAGGCG*acrA*-PR1 (for pAcrA1)TCAGGGGGAGCCGTTGACCGTC*acrA*-PR2 (for pAcrA2)CCTCTGTTTTTGTTCATATGTAAACCTCG*acrA*-PR3 (for pAcrA3)TGTTTGGTTTTTCGTGCCATATGTCG*acrA*-PR4 (for pAcrA4)TCTGATAGCTCCCAGATCTCACTG*acrA*-PR5 (for pAcrA5)AGTAGCTTCAAGAATATGAACTAAAATTTC*acrA*-PR6 (for pAcrA6)AAGGCTACGTTGCGCCTGTTGAACC*acrA*-PR7 (for pAcrA7)ATCAGTATCGCCGCACGACGG*acrA*-PR8 (for pAcrA8)AGGATGTGTTGTCGTGTCTCCAGCGC*acrA*-PR9 (for pAcrA9)TTCGTGCCATATGTCGGTGAATTTACAG*acrA*-PR10 (for pAcrA10)TGTTTGGTTTTTCGTGCCATATGTCG*acrA*-PR11 (for pAcrA11)CAGCGCTTGTTGTTTGGTTTTTCG*acrA*-PR12 (for pAcrA12)GTCGTGTCTCCAGCGCTTGTTGTTTGG*tolC*-PF1CTTTACCTCGCCACTCATTTCTCCG*tolC*-PF2 (for pTolC1)ATGGCACGTAACGCCAACTTTTTGC*tolC*-PF3 (for pTolC2)GTGCTGCCCTGCTAGCAATAATG*tolC*-PRTCCTTGTTGTGAAGCAGTATTTAGCG

*Construction of Gene Deletion Mutants*---Genes were disrupted as described by Datsenko and Wanner ([@ref39]). The chloramphenicol resistance *cat* gene, flanked by Flp recognition sites, was amplified by PCR using the primers listed in [Table 2](#tbl2){ref-type="table"}. The resulting PCR products were used to transform the recipient ATCC14028s strain harboring the pKD46 plasmid that expresses Red recombinase. Chromosomal structure of the mutated loci was verified by PCR ([@ref39]). The deletions were transferred to strains by P22 transduction. The *cat* gene was eliminated using plasmid pCP20 ([@ref39]).

β*-Galactosidase Assays*---Single colonies of each bacterial strain to be assayed were inoculated into 2 ml of LB containing the appropriate selected antibiotics. After overnight growth at 37 °C, the cultures were diluted to 1:50 into *E. coli* conditioned medium or LB media. The cells were then grown at 37 °C until the optical density of 0.8 at 600 nm. To test the effect of indole or bile on gene expression, 2 m[m]{.smallcaps} indole, 0.25 m[m]{.smallcaps} bile salts, 0.25 m[m]{.smallcaps} cholic acid, or 0.25 m[m]{.smallcaps} deoxycholic acid were added to secondary cultures. β-Galactosidase activities were determined as described by Miller ([@ref40]). All assays were performed in triplicate.

*Survival Assay*---*Salmonella* WT strain was grown at 37 °C in LB medium, with or without indole, for 7 h. Benzalkonium was added to create a concentration of 150 mg/ml in LB. After incubation for 10 min, the number of colony-forming units was determined by serial dilutions in phosphate-buffered saline on LB agar. The percentage of cells surviving under benzalkonium was the number of colony-forming units per ml remaining after the benzalkonium treatment divided by the initial number of colony-forming units per ml. Survival levels of the indole-treated cells were standardized to 100%, and untreated cell values were displayed relative to those of the indole-treated cells. All assays were performed in triplicate.

FIGURE 1.**Indole induction of multidrug efflux genes and drug tolerance of *Salmonella enterica* serovar Typhimurium.** The data correspond to mean values from three independent experiments. *Bars* correspond to the standard deviation. *Asterisks* indicate statistically significant differences (^\*^, *p* \< 0.01) in the paired Student\'s *t* test. *A,* differences in β-galactosidase activity in *tolC-lac* (EG15109), *acrAB*-*lac* (NKS505), *acrEF-lac* (EG15114), *acrD-lac* (EG15120), *mdtABC-lac* (EG15124), *mdsABC-lac* (NKS517), *emrAB-lac* (NKS522), *mdfA-lac* (NKS524), *mdtK-lac* (EG15132), and *macAB-lac* (NKS530) strains grown in LB medium with (*solid bars*) or without (*open bars*) 2 m[m]{.smallcaps} indole. *B,* drug tolerance of *S. enterica* serovar Typhimurium induced by indole. WT strain (ATCC14028s) was incubated with or without 2 m[m]{.smallcaps} indole. Cells were then challenged to benzalkonium (500 mg/ml) for 10 min. The survival levels of the indole-treated cells were normalized to 100%, and untreated cells are displayed relative to those of the indole-treated cells. The actual survival of indole-treated cells was 0.025%.

*Preparation of Conditioned Medium*---Conditioned medium was prepared by inoculating 30 ml of LB broth with 300 μl of a 10^-3^ dilution of an overnight culture of *E. coli* MG1655, followed by shaking (170 rpm) at 37 °C for 24 h (*A*~600~ of 5.0) ([@ref41]). The cells were pelleted by centrifugation, and the resulting supernatants supplemented with 20× LB broth to create a final concentration of 0.5× and adjusted to a pH of 7.5. The conditioned medium was then filter-sterilized through a 0.2-μm pore filter.

*Purification of Histidine-tagged RamA and Truncated RamA Protein*---Full-length *ramA* gene or truncated *ramA* gene (69 bases at 5-terminal was deleted) were amplified from genomic DNA of ATCC14028s by PCR with the primers listed in [Table 2](#tbl2){ref-type="table"}. The DNA fragments were cloned into pMALc2x vector (New England Biolabs). Constructed plasmids were transformed into BL21(DE3) to produce histidine-tagged RamA or N-terminal truncated (23 amino acids) His-RamA. For purification of RamA protein, *E. coli* was grown at 37 °C to an *A*~600~ of 0.5. RamA production was induced by addition of 0.3 m[m]{.smallcaps} isopropyl 1-thio-β-[d]{.smallcaps}-galactoside. Cultures were incubated for 3 h, and bacterial cells were then disrupted by French press (SLM Instruments, Inc., Urbana, IL). The protein was purified using TALON metal affinity resin (Clontech).

*DNA Mobility Shift Assay*---Upstream regions of *acrA* and *tolC* were amplified by PCR. The PCR products were purified for a DNA mobility shift assay. Ten microliters of reaction mixture for the DNA mobility shift assay contained 0.15 pmol of DNA and RamA protein. The reaction buffer contained 10 m[m]{.smallcaps} Tris-HCl (pH 7.5), 50 m[m]{.smallcaps} KCl, and 1 m[m]{.smallcaps} dithiothreitol. Reaction mixtures were incubated for 30 min at room temperature and separated on a 5% native polyacrylamide gel at 4 °C. The gel was soaked in 10,000× diluted SYBR Green I nucleic acid stain (Cambrex Corp., East Rutherford, NJ). DNA was visualized under blue incident light at 460 nm (Luminescent Image Analyzer LAS-3000, Fujifilm Life Science, Stamford, CT).

*Intrinsic Fluorescence Spectrum of RamA in the Presence of Cholic Acid*---Fluorescence spectra of RamA and truncated RamA were measured as described by Rosenberg *et al.* ([@ref31]). The fluorescence emission spectra were recorded using a LS 55 fluorescence spectrometer, 120 V (PerkinElmer Life Sciences).

RESULTS
=======

*Indole Induces Four Multidrug Efflux Pumps and Drug Tolerance of Salmonella*---In *E. coli*, indole is produced from tryptophan by tryptophanase and is excreted from the cell ([@ref42]). However, *Salmonella* does not produce indole because it lacks the *tnaA* gene encoding tryptophanase ([@ref43]). Indole has also been reported to auto-regulate multidrug efflux genes in *E. coli* ([@ref35]). We postulated that *Salmonella* multidrug efflux genes may respond to indole. To investigate the effect of indole on the expression of multidrug efflux pumps, *Salmonella* strains, in which the efflux genes were replaced with a reporter gene (*lacZ*), were inoculated into cultures, with or without indole. Expression levels of drug efflux pumps were measured by a β-galactosidase reporter assay. Indole significantly induced expression of the *acrAB, emrAB, acrD*, and *mdtABC* efflux genes in *Salmonella* ([Fig. 1*A*](#fig1){ref-type="fig"}). A survival assay using benzalkonium showed that indole enhanced drug tolerance of *Salmonella* ([Fig. 1*B*](#fig1){ref-type="fig"}).

*Indole Induces acrAB Expression via the RamA Regulator*---Among the multidrug efflux pumps, AcrAB plays a major role in the intrinsic resistance of *Salmonella* ([@ref25]). Also, Hirakawa *et al.* ([@ref35]) reported that the *baeSR* and *cpxAR* signal transduction system genes are required for indole induction of multidrug efflux pumps in *E. coli*. To identify the regulatory elements that induce *acrAB* in response to indole in *Salmonella*, we constructed a mutant that lacked *baeSR* and *cpxAR*. In the Δ*baeSR cpxAR* mutant, the expression of *acrAB* was not significantly different from that in the wild-type (WT) strain; however, indole induction of *acrD* was significantly lower in the mutant compared with the WT strain ([Fig. 2*A*](#fig2){ref-type="fig"}). The result indicates that the BaeSR and CpxAR signal transduction systems are not involved in indole induction of *acrAB,* whereas they are required for *acrD* induction. Other regulators, *marA, soxS, rob, sdiA*, and *acrR*, have been previously reported to control *acrAB* expression in *E. coli* ([@ref27]). With the exception of *ramA*, none significantly altered the indole induction of *acrAB* in *Salmonella* ([Fig. 2*B*](#fig2){ref-type="fig"}). The stimulatory effect of indole on *acrAB* expression was completely eliminated in the Δ*ramA* mutant ([Fig. 2*B*](#fig2){ref-type="fig"}). The results indicate that the RamA regulator is required for indole induction of *acrAB* in *Salmonella*.

FIGURE 2.**Indole activation of *acrAB* expression through the RamA regulator.** The data correspond to mean values from three independent experiments. *Bars* correspond to the standard deviation. *Asterisks* indicate statistically significant differences (^\*^, *p* \< 0.01) in the paired Student\'s *t* test. *A,* β-galactosidase levels in WT or Δ*baeSR cpxAR* strains, carrying *acrAB-lac* and *acrD-la*c transcriptional fusions, grown in LB medium with (*solid bars*) or without (*open bars*) 2 m[m]{.smallcaps} indole. *B,* β-galactosidase levels were assayed in strains carrying the *acrAB-lac* transcriptional fusion in the WT (NKS505), Δ*marA* (NES20), Δ*rob* (NES29), Δ*soxS* (NES28), Δ*sdiA* (NES35), Δ*acrR* (NES48), Δ*marA rob soxS sdiA acrR* (NES55), and Δ*ramA* (NES58) strains. Strains were grown in LB medium with (*solid bars*) or without (*open bars*) 2 m[m]{.smallcaps} indole.

FIGURE 3.**Requirement of RamA for induction of *acrAB* by bile.** β-Galactosidase levels were assayed in WT (NKS505) or Δ*ramA* (NES58) strains carrying the *acrAB-lac* transcriptional fusion. Cells were grown in LB medium (control) or LB medium supplemented with 0.25 m[m]{.smallcaps} cholic acid, 0.25 m[m]{.smallcaps} deoxycholic acid, or 0.25 m[m]{.smallcaps} bile salts. The data correspond to mean values from three independent experiments. *Bars* correspond to the standard deviation. Student\'s *t* test; ^\*^, *p* \< 0.01 *versus* WT.

FIGURE 4.**Multidrug efflux genes in *Salmonella enterica* serovar Typhimurium induced by an *E. coli* conditioned medium.** The *tolC-lac* (EG15109), *acrAB*-*lac* (NKS505), *acrEF-lac* (EG15114), *acrD-lac* (EG15120), *mdtABC-lac* (EG15124), *mdsABC-lac* (NKS517), *emrAB-lac* (NKS522), *mdfA-lac* (NKS524), *mdtK-lac* (EG15132), and *macAB-lac* (NKS530) strains were grown in conditioned medium prepared from *E. coli* culture. Expression levels of multidrug efflux genes were determined by β-galactosidase assay. The data correspond to mean values of three independent experiments. *Error bars* correspond to the standard deviation. *Asterisks* indicate statistically significant differences (^\*^, *p* \< 0.01) in the paired Student\'s *t* test.

*acrAB Activation by Bile Is Dependent on the RamA Regulator*---The AcrAB pump is reported to export bile salts and play a role in bile resistance in *E. coli* and *Salmonella* ([@ref44]-[@ref46]). Also, *acrAB* is reportedly induced by bile in a Robdependent manner in *E. coli* ([@ref31]). Although *acrAB* is also induced by bile in *Salmonella*, the induction mediating regulator is unknown ([@ref47]). Prouty *et al.* ([@ref47]) further reported that *acrAB* activation by bile is independent of MarA, Rob, PhoP/PhoQ, and RpoS. We investigated the possibility that RamA controls *acrAB* expression in response to bile. In agreement with Prouty *et al.* ([@ref47]), bile salts, cholic acid, and deoxycholic acid significantly induced *acrAB* expression in *Salmonella* ([Fig. 3](#fig3){ref-type="fig"}). When *ramA* was deleted, *acrAB* induction was eliminated ([Fig. 3](#fig3){ref-type="fig"}). These findings indicate a novel RamA-dependent pathway for bile-mediated regulation of the AcrAB efflux pump in *Salmonella*, different from that observed in *E. coli*.

*Conditioned Medium from E. coli Induces Salmonella acrAB and tolC Genes via the RamA Regulator*---Indole accumulates and MdtEF is induced in stationary phase cultures of *E. coli*, but experiments with a *tnaAB* mutant showed that indole partially contributes to this induction ([@ref48]). These results indicate that *E. coli* produces indole as well as other efflux pump inducers. Therefore, we investigated whether an *E. coli* conditioned medium would induce multidrug efflux pumps in *Salmonella*. Conditioned medium, prepared from *E. coli* MG1655, significantly induced eight *Salmonella* multidrug efflux pumps, including *acrAB* and the outer membrane protein gene *tolC* ([Fig. 4](#fig4){ref-type="fig"}). Inductions of *acrAB* and *tolC* were significantly decreased in Δ*ramA* ([Fig. 5, *A* and *B*](#fig5){ref-type="fig"}), indicating that the *E. coli* conditioned medium induced *acrAB* and *tolC* via the RamA regulator.

FIGURE 5.**RamA induction of *acrAB* and *tolC* by conditioned medium of *E. coli***. The expression of *acrAB* (*A*) and *tolC* (*B*) determined by β-galactosidase assay using strains *acrAB-lac* (NKS505), Δ*ramA*/*acrAB-lac* (NES58), *tolC-lac* (EG15109), or Δ*ramA*/*tolC-lac* (NES65) grown in LB medium or conditioned medium from *E. coli* MG1655. The data correspond to mean values from three independent experiments. *Bars* correspond to the standard deviation. *Asterisks* indicate statistically significant differences (^\*^, *p* \< 0.01) in the paired Student\'s *t* test.

*RamA Binds to the Upstream Regions of acrA and tolC*---The aforementioned results indicate that RamA plays a major role in inducing *acrAB* in response to environmental signals such as indole and bile. To understand the regulation of *acrAB* by RamA, electrophoretic mobility shift assays (EMSA) with the RamA protein were performed. Plasmids encoding the histidine-tagged RamA or the N terminus truncated RamA proteins were constructed ([Table 2](#tbl2){ref-type="table"}). Because it was reported that RamA overproduction was related to increased AcrAB expression in clinical *Klebsiella pneumoniae* isolates ([@ref49]), we investigated the effect of histidine-tagged RamA on *acrAB* expression. Overproduction of histidine-tagged RamA significantly induced the expression of *acrAB* ([Fig. 6*A*](#fig6){ref-type="fig"}); however, the truncated RamA did not induce *acrAB* ([Fig. 6*A*](#fig6){ref-type="fig"}) and was used as a negative control in subsequent EMSA. Upstream regions of *acrA* were amplified by PCR, and the fragments were incubated with RamA or truncated RamA protein. RamA bound to pAcrA1, whereas truncated RamA did not ([Fig. 6*B*](#fig6){ref-type="fig"}). However, RamA did not bind to pAcrA2, indicating that the RamA-binding site is located between -795 and -142 upstream of *acrA* ([Fig. 6*B*](#fig6){ref-type="fig"}). RamA did bind to the upstream region of *tolC,* whereas the truncated RamA did not ([Fig. 6*C*](#fig6){ref-type="fig"}). These results indicate that RamA directly controls the expression of *acrAB* and *tolC*.

FIGURE 6.**RamA binds to the upstream region of *acrA* and *tolC***. *A,* β-galactosidase activity measured with *acrAB*-*lac* (NKS505) harboring a plasmid expressing *ramA*, truncated *ramA*, or the vector control (pMALc2X). The data correspond to mean values from three independent experiments. *Error bars* correspond to the standard deviation. Student\'s *t* test; ^\*^, *p* \< 0.01 *versus* control. *B* and *C,* EMSA images for RamA binding to the upstream regions of *acrA* (*B*) and *tolC* (*C*). Upstream regions of *acrA* (*pAcrA1*, -795 to +16 region relative to the start codon of *acrA*; *pAcrA2*, -141 to +16) (*A*) and *tolC* (-250 to -1 region relative to the start codon of *tolC*)(*C*) were incubated with various concentrations of RamA or N-terminal truncated RamA. Protein concentrations are as follows: -, without protein; +, 1.0 μ[m]{.smallcaps}; ++, 1.5 μ[m]{.smallcaps}; +++, 2.0 μ[m]{.smallcaps}.

*Determination of RamA-binding Sites for acrA and tolC*---To determine the RamA-binding site for *acrA*, we prepared different lengths of DNA fragments for EMSA. The fragments used were as follows: pAcrA3 (-241 to +16, the numbering is relative to the start codon of *acrA*), pAcrA4 (-341 to +16), pAcrA5 (-441 to +16), pAcrA6 (-541 to +16), and pAcrA7 (-641 to +16). RamA bound to pAcrA3-7, but it did not bind to pAcr2 ([Fig. 7*A*](#fig7){ref-type="fig"}). These results indicate that the RamA-binding site was between -241 and -142. We then examined fragment pAcrA8 (-191 to +16); RamA bound to this fragment, indicating a binding site between -191 and -142 ([Fig. 7*B*](#fig7){ref-type="fig"}). Further examination with pAcrA9 (-151 to +16), pAcrA10 (-161 to +16), pAcrA11 (-171 to +16), and pAcrA12 (-181 to +16) revealed that RamA bound to pAcrA10-12 but not to pAcrA9 ([Fig. 7*C*](#fig7){ref-type="fig"}). These results indicate that the -161 to -152-bp region is required for RamA binding. It was previously reported that RamA bound to a 20-bp asymmetric sequence with a degenerate consensus soxbox of A*YN*GCAC-*NNWNNRYY*AAA*YN* (*N* = any base; *R* = A/G; *W* = A/T; *Y* = C/T) ([@ref50], [@ref51]). A DNA sequence resembling this consensus soxbox sequence, ATGGCACGAAAAACCAAACA, was located at -161 to -142 ([Fig. 7*D*](#fig7){ref-type="fig"}).

We also determined a RamA-binding site located upstream of *tolC*. In a *tolC* promoter, we found a soxbox sequence between -99 and -80 (the numbering is relative to the start codon of *tolC*). Therefore, we prepared fragments of pTolC1 (-79 to -1) and pTolC2 (-99 to -1) to determine binding location. RamA bound to pTolC2 but did not bind to pTolC1 ([Fig. 8*A*](#fig8){ref-type="fig"}) indicating that RamA binds between -99 to -80 and contains the ATGGCACGTAACGCCAACTT consensus sequence ([Fig. 8*B*](#fig8){ref-type="fig"}).

*Indole Induces ramA Expression but Bile Does Not*---The effects of indole and bile on *ramA* expression levels were investigated because increased *ramA* expression has been reported to cause increased production of the AcrAB-TolC efflux system ([@ref49]). Using a reporter plasmid of *ramA*, a β-galactosidase assay showed that indole enhanced the promoter activity of *ramA* ([Fig. 9](#fig9){ref-type="fig"}). This suggests that indole induces *acrAB* through increased expression of *ramA*. Bile salts, cholic acid, and deoxycholic acid did not affect the expression level of *ramA* despite its requirement for induction of *acrAB*. This indicates an *acrAB* regulatory mode other than through increased production of RamA.

*Binding of Bile to RamA Protein*---The failure of bile to affect the expression level of *ramA* suggests that RamA may detect the presence of a bile acid component such as cholic acid. This was explored using the intrinsic (tryptophan) spectrum of RamA, as described by Rosenberg *et al.* ([@ref31]). When 50 μ[m]{.smallcaps} cholic acid was added to 75 n[m]{.smallcaps} RamA, there was a strong blue shift in the emission spectrum ([Fig. 10*A*](#fig10){ref-type="fig"}). The blue shift was also slightly seen with 10 μ[m]{.smallcaps} cholic acid and 75 n[m]{.smallcaps} RamA ([Fig. 10*B*](#fig10){ref-type="fig"}). In contrast, a blue shift was not observed when 50 μ[m]{.smallcaps} cholic acid was added to 75 n[m]{.smallcaps} truncated RamA ([Fig. 10*C*](#fig10){ref-type="fig"}). These results indicate that bile binds to RamA to induce *acrAB* expression in *Salmonella*.

FIGURE 7.*A-C,* determination of RamA-binding site for *acrA*. EMSA of RamA binding to the upstream regions of *acrA* is shown. DNA fragments, including upstream regions of *acrA,* were incubated without (-) or with (+) purified RamA (1.0 μ[m]{.smallcaps}). DNA fragments are as follows: pAcr2 (-141 to +16, the numbering is relative to the start codon of *acrA*), pAcrA3 (-241 to +16), pAcrA4 (-341 to +16), pAcrA5 (-441 to +16), pAcrA6 (-541 to +16), pAcrA7 (-641 to +16) (*A*), pAcrA8 (-191 to +16) (*B*), pAcrA9 (-151 to +16), pAcrA10 (-161 to +16), pAcrA11 (-171 to +16), and pAcrA12 (-181 to +16) (*C*). *D,* nucleotide sequence in the upstream region of *acrA. Boxed* sequence corresponds to the RamA-binding site. The *numbers* indicate the positions from the start codon of *acrA*.

FIGURE 8.**RamA-binding site for *tolC***. *A,* DNA fragments, including *tolC* promoter regions pTolC1 (-80 to -1; the numbering is relative to the start codon of *tolC*) and pTolC2 (-100 to +1), were incubated without (-) or with (+) purified RamA (1.0 μ[m]{.smallcaps}). *B,* nucleotide sequence upstream region of *tolC. Boxed* sequence corresponds to the RamA-binding site. The *numbers* indicate the positions from the start codon of *tolC*.

FIGURE 9.**Effect of indole and bile on *ramA* transcription.** β-Galactosidase levels were assayed in the WT strain carrying the *ramA* reporter plasmid (pNN*ramA*) (NES84). Cells were grown in LB medium supplemented with 2 m[m]{.smallcaps} indole, 0.25 m[m]{.smallcaps} cholic acid, 0.25 m[m]{.smallcaps} deoxycholic acid, or 0.25 m[m]{.smallcaps} bile salts. The data correspond to mean values from three independent experiments. *Bars* correspond to the standard deviation. Student\'s *t* test; ^\*^, *p* \< 0.01 *versus* control.

DISCUSSION
==========

Very few signals inducing multidrug efflux pumps in *Salmonella* have been identified so far ([@ref47], [@ref52]). In this study, we found that indole, bile, and an *E. coli* conditioned medium induced several multidrug efflux genes in *Salmonella*. We found that *acrAB* induction by these three signal sources is completely dependent on the *Salmonella*-specific regulator RamA, indicating that RamA plays a major role in inducing *acrAB*. RamA belongs to the AraC transcriptional activator family, and activation of RamA is reported to confer drug resistance on *Salmonella* ([@ref53]). In *Salmonella*, RamA is also involved in resistance to superoxide ([@ref54]) and in paraquat induction of the flavohemoglobin gene ([@ref50]).

The *ramA* gene appears to be specific for *Salmonella* serovars and is absent in many other Gram-negative microorganisms; notable exceptions are *K. pneumoniae* and *Enterobacter* spp. ([@ref54]-[@ref56]). The results of genomic comparison indicate that the gene organization surrounding *ramA* gene and the corresponding region in *E. coli* are similar, with two exceptions as follows: the absence of *ramA* and the presence of *Yi81-2* in *E. coli* ([@ref57]). We suggest that the AcrAB induction pathway in *Salmonella* is different from that in *E. coli*. Bile induces AcrAB in both *Salmonella* and *E. coli*. In *E. coli*, the transcriptional factor Rob plays a major role in inducing *acrAB* expression in response to bile ([@ref31]). However, our data indicate that bile induction of *acrAB* in *Salmonella* is completely dependent on RamA, not Rob. Other regulators, including MarA, SoxS, SdiA, and AcrR, are not involved in AcrAB induction by indole and bile. These results suggest that RamA is a master regulator of *Salmonella acrAB* and may mask the contributions of any other *acrAB* regulators. In *E. coli*, it was reported that multiple regulators, including MarA, Rob, SoxS, and SdiA, work coordinately in controlling *acrAB* expression in response to *acrAB* inducers. This may be related to the lack of RamA in *E. coli*. Indeed, overproduction of RamA has induced the drug resistance level of *E. coli* ([@ref53], [@ref57]). A recent report suggests that RamA and RamR, not SoxS and MarA, are involved in AcrAB-mediated multidrug resistance in *Salmonella* ([@ref58]). Based on our results and these other studies, RamA appears to be the master regulator of *acrAB* in *Salmonella*.

FIGURE 10.**Binding of bile to the RamA protein.** *A,* cholic acid (50 μ[m]{.smallcaps}) produces a blue shift in the intrinsic spectrum of RamA. Intrinsic fluorescence of RamA (75 n[m]{.smallcaps}) was measured in the absence or presence of cholic acid. *B,* cholic acid (10 μ[m]{.smallcaps}) also produces a blue shift in the intrinsic spectrum of RamA. *C,* blue shift in the intrinsic spectrum of truncated RamA was not produced by 50 μ[m]{.smallcaps} cholic acid.

FIGURE 11.**Proposed model for the expression of *acrA* and *acrB* multidrug efflux genes by RamA.** In one pathway, bile may bind to the RamA protein, which is then converted from a low to a high activity state. In the other path, indole may activate *ramA* transcription to directly induce *acrA* and *acrB*.

We also suggest the existence of a different induction mechanism for *acrAB* via the RamA regulator ([Fig. 11](#fig11){ref-type="fig"}). Indole was shown to induce *ramA* expression ([Fig. 9](#fig9){ref-type="fig"}), and such an increased expression of *ramA* can induce *acrAB* ([Fig. 6*A*](#fig6){ref-type="fig"}). On the other hand, bile did not affect expression of *ramA* ([Fig. 9](#fig9){ref-type="fig"}), but it did bind to RamA ([Fig. 11](#fig11){ref-type="fig"}). This is reminiscent of the binding of bile to the Rob protein involved in regulation of *acrAB* in *E. coli* ([@ref31]). We also suggest that the N-terminal domain of RamA may be required for binding of bile because cholic acid did not bind to the truncated RamA ([Fig. 10](#fig10){ref-type="fig"}). Our results suggest a mechanism in which RamA can change between an "activated state" and an "overexpressed state" in response to environmental signals, thereby inducing the AcrAB-TolC system ([Fig. 11](#fig11){ref-type="fig"}). Thus, RamA can be converted from a low activity state to a high activity state in response to bile. We also suggest that *Salmonella* may have an additional sensor for indole that controls *ramA* expression ([Fig. 11](#fig11){ref-type="fig"}).

Indole and bile are found in various internal human environments, especially in the intestine ([@ref59], [@ref60]). Indole is produced by many enteric bacterial species ([@ref60]), and bile is often present at high concentration in the intestinal tract ([@ref59]). Therefore, RamA may be required for *Salmonella* to detect environmental signals and for subsequent induction of the AcrAB-TolC system, resulting in excretion of toxic compounds by *Salmonella* into surrounding environments, such as the intestine.
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